---

Highlights of December 2023

1.      JB Chem to acquire select ophthalmology brands of Novartis India for INR 1,089 crores (~US$131 Million).

2.      Sun Pharma has entered into a licensing agreement with Aclaris Therapeutics, Inc with upfront payment of US$ 15 Million (about Rs 125 crore).

3.      Lupin to acquire established products in Europe and Canada from Sanofi for INR 91Crores (~US$ 11 Million)

4.      Medtronic doubles down on endoscopy AI partnership, inking $200M deal with Cosmo Pharmaceuticals.

5.      Editas licenses CRISPR patents to Vertex in $100 million-plus deal

6.      Proteomedix acquired by Blue Water Biotech to form Onconetix.

7.      Meril Life Sciences inks pact with Japan Lifeline to expand presence globally.

8.      Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical to develop and market Leuprolide injectable in the US.

9.      AstraZeneca Pharma India, Roche Diagnostics India ink MoU to improve breast cancer diagnostics.

10.  Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience.

11.  Roche Breaks into the Obesity Drug Market with the Acquisition of Carmot Therapeutics.

12.  Pfizer Denmark, Pharmadanmark and the Novo Nordisk Foundation have initiated the alliance and aim to prevent the growing spread of antimicrobial resistance (AMR).

 

Aagami Updates (Recap) of 2023:

1. 1.    Aagami served 19 clients from across the globe.

   2.      Aagami brought deals/term sheet discussions to 5 clients.

   3.      Attended major global conferences such as:

   a.       Biotech Showcase, San Francisco (attending in Jan 2024 too)

   b.       DCAT – New York

   c.       BIO International, Boston

   d.       Bio Japan, Tokyo and

   e.       BIO EU, Munich

   4.       Collaborating with affiliate specialist for market intelligence offerings to clients

   5.       Collaborating on IP and Valuation support with partner who are specialists in the field.

   6.       In Dec 2023, Aagami completed 21 years in business.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

• 1.      Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®. Other high potential Biosimilars are also available for multiple regions.
• 2.      Partnering/Licensing: A small molecule NSAID combination for Migraine using 505(b)(2)
• 3.      Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).
• 4.      Seeking Licensing/Co-development:  A phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity from Japanese client.

For Acquisition:

1.      Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

 2.    IP/Asset sale: A small molecule NSAID combination for Migraine using 505(b)(2)

3.   Asset sale –US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking US$15 million: Nose to brain delivery (intra-nasal and bypassing the blood brain barrier) technology development company targeting orphan diseases such as FrontoTemporal Dementia (FTD), Alzheimer’s disease, Dementia with Lewy Bodies and Parkinson's disease.
2. Invest: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance treatments and diagnostics
3. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfils an unmet need for treating Bacterial Dysentery.
4. Seeking US$5 million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.

We wish you a very happy and successful 2024 and beyond.